Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.

Fan-Havard P, Liu Z, Chou M, Ling Y, Barrail-Tran A, Haas DW, Taburet AM; ANRS12154 Study Group.

Antimicrob Agents Chemother. 2013 May;57(5):2154-60. doi: 10.1128/AAC.02294-12. Epub 2013 Mar 4.

2.

Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.

Haas DW, Gebretsadik T, Mayo G, Menon UN, Acosta EP, Shintani A, Floyd M, Stein CM, Wilkinson GR.

J Infect Dis. 2009 Mar 15;199(6):872-80. doi: 10.1086/597125.

3.

Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.

Chantarangsu S, Cressey TR, Mahasirimongkol S, Capparelli E, Tawon Y, Ngo-Giang-Huong N, Jourdain G, Lallemant M, Chantratita W.

J Antimicrob Chemother. 2009 Dec;64(6):1265-73. doi: 10.1093/jac/dkp351. Epub 2009 Oct 6.

4.

Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.

Vardhanabhuti S, Acosta EP, Ribaudo HJ, Severe P, Lalloo U, Kumarasamy N, Taulo F, Kabanda J, Oneko O, Ive P, Sambarey P, Chan ES, Hitti J, Hong F, McMahon D, Haas DW; A5207 ACTG Study Team.

J Infect Dis. 2013 Aug 15;208(4):662-71. doi: 10.1093/infdis/jit223. Epub 2013 May 17.

5.

Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.

Chou M, Bertrand J, Segeral O, Verstuyft C, Borand L, Comets E, Le Tiec C, Becquemont L, Ouk V, Mentre F, Taburet AM.

Antimicrob Agents Chemother. 2010 Oct;54(10):4432-9. doi: 10.1128/AAC.00512-10. Epub 2010 Aug 9.

6.

Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.

Calcagno A, D'Avolio A, Simiele M, Cusato J, Rostagno R, Libanore V, Baietto L, Siccardi M, Bonora S, Di Perri G.

Br J Clin Pharmacol. 2012 Jul;74(1):134-40. doi: 10.1111/j.1365-2125.2012.04163.x.

7.

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.

Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, Bogner JR, Rockstroh J, Esser S, Jaeger H, Harrer T, Mauss S, van Lunzen J, Skoetz N, Jetter A, Groneuer C, Fätkenheuer G, Khoo SH, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS.

J Antimicrob Chemother. 2008 Apr;61(4):914-8. doi: 10.1093/jac/dkn029. Epub 2008 Feb 14.

8.

CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.

Chen J, Sun J, Ma Q, Yao Y, Wang Z, Zhang L, Li L, Sun F, Lu H.

Ther Drug Monit. 2010 Oct;32(5):573-8. doi: 10.1097/FTD.0b013e3181ea953c.

PMID:
20625352
9.

Disposition and biotransformation of the antiretroviral drug nevirapine in humans.

Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, Keirns J.

Drug Metab Dispos. 1999 Aug;27(8):895-901.

10.

Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.

Chokephaibulkit K, Cressey TR, Capparelli E, Sirisanthana V, Muresan P, Hongsiriwon S, Ngampiyaskul C, Limwongse C, Wittawatmongkol O, Aurpibul L, Kabat B, Toye M, Smith ME, Eksaengsri A, McIntosh K, Yogev R; IMPAACT P1069 Team.

Antivir Ther. 2011;16(8):1287-95. doi: 10.3851/IMP1931.

11.

Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?

Micheli JE, Chinn LW, Shugarts SB, Patel A, Martin JN, Bangsberg DR, Kroetz DL.

Pharmacogenet Genomics. 2013 Nov;23(11):591-6. doi: 10.1097/FPC.0b013e32836533a5.

12.

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.

Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M, Davies G, Khoo S, Fätkenheuer G, Youle M, Rockstroh J, Brockmeyer NH, Johnson MA, Owen A, Back DJ; German Competence Network for HIV/AIDS.

J Antimicrob Chemother. 2011 Jun;66(6):1332-9. doi: 10.1093/jac/dkr087. Epub 2011 Mar 25.

13.

Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India.

Swaminathan S, Ramachandran G, Agibothu Kupparam HK, Mahalingam V, Soundararajan L, Perumal Kannabiran B, Navaneethapandian PG, Shah I, Karunaianandham R, Sikhamani R.

J Antimicrob Chemother. 2011 Jun;66(6):1354-9. doi: 10.1093/jac/dkr075. Epub 2011 Mar 9.

14.

Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.

Brown KC, Hosseinipour MC, Hoskins JM, Thirumaran RK, Tien HC, Weigel R, Tauzie J, Shumba I, Lamba JK, Schuetz EG, McLeod HL, Kashuba AD, Corbett AH.

Pharmacogenomics. 2012 Jan;13(1):113-21. doi: 10.2217/pgs.11.132. Epub 2011 Nov 23.

15.

Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.

Dickinson L, Chaponda M, Carr DF, van Oosterhout JJ, Kumwenda J, Lalloo DG, Pirmohamed M, Heyderman RS, Khoo SH.

Antimicrob Agents Chemother. 2014;58(2):706-12. doi: 10.1128/AAC.02069-13. Epub 2013 Nov 11.

16.

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.

van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH, Hoetelmans RM.

AIDS. 2000 May 26;14(8):F77-82.

PMID:
10853971
17.

Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.

Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, Alfaro RM, Kityo C, Formentini E, Masur H.

HIV Med. 2007 Mar;8(2):86-91.

18.

Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography-tandem mass spectrometry.

Rowland LS, MacGregor TR, Campbell SJ, Jenkins R, Pearsall AB, Morris JP.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):252-60. Epub 2007 Jun 22.

PMID:
17618842
19.

Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine.

Ramachandran G, Ramesh K, Hemanth Kumar AK, Jagan I, Vasantha M, Padmapriyadarsini C, Narendran G, Rajasekaran S, Swaminathan S.

J Antimicrob Chemother. 2009 Apr;63(4):841-3. doi: 10.1093/jac/dkp033. Epub 2009 Feb 13. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk